Movement Alert｜Incyte Rises 5.84% in Regular Trading, Opzelura Receives Positive EU CHMP Opinion for Atopic Dermatitis

Market Focus06-27

On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for adults with moderate atopic dermatitis who have not responded adequately to standard topical therapies.

The CHMP recommendation is based on Phase 3 TRuE-AD4 data showing significant improvements in disease severity and symptoms, with the treatment generally well tolerated. If approved by the European Commission, Opzelura would become the first steroid-free topical JAK inhibitor in the EU for this patient population. This regulatory milestone represents a key step toward expanding the drug's commercial footprint in Europe, adding to Incyte's growing portfolio across hematology, oncology, and inflammation therapeutics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138480022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-27 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138480022","market":"us","top_or_hot":-1,"title":"Movement Alert｜Incyte Rises 5.84% in Regular Trading, Opzelura Receives Positive EU CHMP Opinion for Atopic Dermatitis","media":"Market Focus","content":"<p><p>On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for adults with moderate atopic dermatitis who have not responded adequately to standard topical therapies.</p><p>The CHMP recommendation is based on Phase 3 TRuE-AD4 data showing significant improvements in disease severity and symptoms, with the treatment generally well tolerated. If approved by the European Commission, Opzelura would become the first steroid-free topical JAK inhibitor in the EU for this patient population. This regulatory milestone represents a key step toward expanding the drug's commercial footprint in Europe, adding to Incyte's growing portfolio across hematology, oncology, and inflammation therapeutics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Incyte Rises 5.84% in Regular Trading, Opzelura Receives Positive EU CHMP Opinion for Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Incyte Rises 5.84% in Regular Trading, Opzelura Receives Positive EU CHMP Opinion for Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-27 00:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for adults with moderate atopic dermatitis who have not responded adequately to standard topical therapies.</p><p>The CHMP recommendation is based on Phase 3 TRuE-AD4 data showing significant improvements in disease severity and symptoms, with the treatment generally well tolerated. If approved by the European Commission, Opzelura would become the first steroid-free topical JAK inhibitor in the EU for this patient population. This regulatory milestone represents a key step toward expanding the drug's commercial footprint in Europe, adding to Incyte's growing portfolio across hematology, oncology, and inflammation therapeutics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"","article_id":"1138480022","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138480022","pubTimestamp":1782490533,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"异动警报|Incyte常规交易涨5.84%，Opzelura获得欧盟CHMP对特应性皮炎的积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"On June 27, Incyte rose 5.84% in regular trading, trading at $113.78/share, with turnover of $140 million. The rally was driven by the company's announcement that its Opzelura cream received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval for adults with moderate atopic dermatitis who have not responded adequately to standard topical therapies.The CHMP recommendation is based on Phase 3 TRuE-AD4 data showing significant improvements in disease severity and symptoms, with the treatment generally well tolerated. If approved by the European Commission, Opzelura would become the first steroid-free topical JAK inhibitor in the EU for this patient population. This regulatory milestone represents a key step toward expanding the drug's commercial footprint in Europe, adding to Incyte's growing portfolio across hematology, oncology, and inflammation therapeutics.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138480022","isCrawlerRequest":true}